Compare UFI & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFI | MAIA |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 69.2M |
| IPO Year | 1994 | 2022 |
| Metric | UFI | MAIA |
|---|---|---|
| Price | $5.54 | $1.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 60.1K | ★ 522.0K |
| Earning Date | 11-03-2026 | 11-06-2026 |
| Dividend Yield | ★ 30.77% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $531,303,000.00 | N/A |
| Revenue This Year | $4.12 | N/A |
| Revenue Next Year | $9.69 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $0.87 |
| 52 Week High | $8.47 | $3.19 |
| Indicator | UFI | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 30.46 | 41.15 |
| Support Level | $3.62 | N/A |
| Resistance Level | $6.79 | $1.47 |
| Average True Range (ATR) | 0.26 | 0.05 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 9.66 | 38.89 |
Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.